NCT00818480 2015-09-04An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155Astellas Pharma IncPhase 2 Completed10 enrolled
NCT01009775 2015-09-04A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV MelanomaAstellas Pharma IncPhase 2 Completed64 enrolled
NCT00281541 2012-06-07A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV MelanomaAstellas Pharma IncPhase 2 Completed29 enrolled